Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study - PubMed
2 days ago
- #PSA
- #Prostate Cancer Screening
- #BRCA1/BRCA2
- The IMPACT study evaluated targeted PSA screening in BRCA1/BRCA2 pathogenic germline variant (PGV) carriers over 5 years.
- BRCA2 PGV carriers had a significantly higher incidence of clinically significant prostate cancer (csPC) compared to noncarriers (3.1% vs 1.3%).
- BRCA1/BRCA2 PGV carriers had a higher proportion of intermediate/high-risk prostate cancers compared to noncarriers.
- No T4 or metastatic prostate cancer cases were detected in the screened cohort.
- Annual PSA screening is recommended for BRCA2 PGV carriers and should be considered for BRCA1 PGV carriers.